Study of the Safety and Effectiveness of Esmirtazapine in Participants With Chronic Primary Insomnia (P05706)

Phase 3

Completed

• Conditions: Insomnia
• Interventions: Drug: Esmirtazapine; Drug: Placebo

• Registration Number: NCT00482612
• Lead Sponsor: Merck Sharp & Dohme LLC

Brief Summary

The purpose of this study is to determine if esmirtazapine (Org 50081) is a safe and effective treatment for insomnia. It was anticipated that esmirtazapine would increase mean Total Sleep Time (TST) as recorded in sleep diaries relative to placebo.

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2006-12-07
• Study First Submitted: 2007-06-01
• Study First Submitted QC: 2007-06-04
• Study First Posted: 2007-06-05
• Primary Completion: 2008-08-11
• Study Completion: 2008-08-11
• Disposition First Submitted: 2009-04-29
• Disposition First Submitted QC: 2009-10-02
• Disposition First Posted: 2009-10-06
• Results First Submitted: 2014-06-09
• Results First Submitted QC: 2014-06-09
• Results First Posted: 2014-07-10
• Status Verified: 2018-09
• Last Update Submitted: 2018-09-04
• Last Update Posted: 2018-10-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 526

Inclusion Criteria

• Has signed written informed consent after the scope and nature of the investigation was explained to them
• Has difficulty falling asleep, maintaining sleep or has early morning awakenings

Read More

Exclusion Criteria

• Significant medical or psychiatric illness causing sleep disturbances
• Has a history of bipolar disorder or family (immediate family) of suicide
• Has sleep disorder such as sleep related breathing disorder, restless leg syndrome, narcolepsy
• Has significant other medical illness such as acute or chronic pain, heart, kidney or liver disease within the last year
• Currently diagnosed or meets the criteria for Major Depressive Disorder (MDD) or has been treated for MDD with the last 2 years
• Substance abuse, excessive use of alcohol (as determined by the physician) or drug addiction within the last year.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Esmirtazapine 1.5 mg	Esmirtazapine	Esmirtazapine 1.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
Esmirtazapine 4.5 mg	Esmirtazapine	Esmirtazapine 4.5 mg tablet, oral administration in the evening, once daily, for 2 weeks
Placebo	Placebo	Placebo to esmirtazapine
Esmirtazapine 3.0 mg	Esmirtazapine	Esmirtazapine 3.0 mg tablet, oral administration in the evening, once daily, for 2 weeks

Primary Outcome Measures

Name	Time	Method
Average Total Sleep Time (TST) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period	Day 1 to Day 15	TST was defined as the total amount of time (measured in minutes) that was actually spent sleeping the previous night as recorded daily in the participant's sleep diary. TST values over the 14-day active treatment period were averaged for each participant, and average TST was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were present was used in the analysis.

Secondary Outcome Measures

Name	Time	Method
Average Sleep Latency (SL) as Recorded Daily in the Sleep Diary During the 14-day In-treatment Period	Day 1 to Day 15	SL was defined as the duration of time measured in minutes that it took a participant to fall asleep as recorded daily in the participant's sleep diary. SL values over the 14-day active treatment period were averaged for each participant, and average SL was then reported by treatment arm. For participants with missing data, the average of the nights for which TST data were present were used in the analysis.
Number of Participants Experiencing an Adverse Event (AE) During the 14-day In-treatment Period	Day 1 to Day 15	The total number of participants with an AE during the 14-day In-treatment Period was tallied for each treatment arm. An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.
Number of Participants Who Discontinued From Study Treatment Due to an AE During the 14-day In-Treatment Period	Day 1 to Day 15	The total number of participants discontinuing from study treatment due to experiencing an AE was tallied for each treatment arm. An AE was defined as any untoward medical occurrence in a participant or clinical investigation subject administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. An AE could therefore have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.